

Press Release

Immediate Release

Panacea Biotec & Apotex Inc. expand collaboration to launch Prasugrel in USA

New Delhi – 11th Sept 2017:

Panacea Biotec, India's highly progressive research based health management Company, has expanded its existing collaboration with Apotex Inc., the largest Canadian-owned pharmaceutical company, for sales & distribution of **Prasugrel** 5mg and 10mg tablets (generic version of Eli Lilly's Effient) in the USA. The Company has signed an exclusive License and Supply Agreement with Apotex for this purpose. Under the terms of the agreement, Apotex shall be responsible for sales & distribution of the product in the USA and Panacea Biotec shall be responsible for manufacturing and supply.

Panacea Biotec has already received tentative approval from USFDA for its Paragraph – IV first to file ANDA of Prasugrel Hydrochloride 5mg and 10 mg tablets. Under the provisions of the Hatch-Waxman Act, Panacea Biotec will be entitled to 180 days of shared marketing exclusivity for Prasugrel Hydrochloride upon USFDA approval.

Prasugrel is currently having annual sales of approximately \$ 600 million in USA and is indicated for reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).

Panacea Biotec and Apotex are also working on two drug delivery technology based, high barrier to entry anti-cancer generic products under their existing collaboration.

Speaking on the occasion Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec Ltd said "We are excited to further strengthen the collaboration with Apotex by making Prasugrel as part of our existing relationship."



Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

About Apotex Inc.

Apotex Inc. is the largest Canadian-owned pharmaceutical company, employing over 10,000 people in research, development, manufacturing and distribution facilities world-wide. Apotex produces more than 300 generic molecules in approximately 4,000 different dosages and formats which, in Canada, are used to fill over 85 million prescriptions a year - the largest amount of any pharmaceutical company in this country. For 40 years, Apotex has been a trusted name in the Canadian pharmaceutical community, providing patients around the globe with increased access to quality, affordable medicines. Since our founding, we have been dedicated to maintaining sustainable, state-of-the-art processes – processes that ensure our products meet the highest quality and safety standards in all markets. Through our unwavering commitment to excellence and innovation, we help communities across the world live longer, healthier lives. The company operates through affiliates in Canada, the US, Australia, Belgium, Central America, Czech Republic, Mexico, the Netherlands, Poland, Spain, New Zealand and Saudi Arabia. It also has manufacturing and distribution facilities worldwide. Apotex is headquartered in Toronto, Ontario, Canada. For more information on the Company, please visit Apotex Inc's website at <http://www.apotex.com>

About Panacea Biotec

Panacea Biotec Limited is a leading biotechnology company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and leading Biotechnology Companies in India. The Company has also been ranked amongst



Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

the top 25 pharmaceutical companies (AIOCD AWACS-MAT MAR-2016) in represented market India.

The product portfolio of includes highly innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular diseases and pediatric vaccines. It is working on a robust pipeline of high barrier to entry generics products, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro-particles, liposomes, gastroretentive systems.

It has introduced its products in over 33 countries across the world including USA and Germany through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international research organizations and corporations.

The company's state-of-the-art manufacturing facilities for vaccines and pharmaceutical formulations comply with several leading regulatory agencies worldwide. The company has around 2,500 employees including around 120 scientists working across 4 R&D centers of the Company.

For more information, please contact –



For Panacea Biotec

Mr. P. D. Karan

Vice President - Corporate Communication & Business Development

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040, + 91 9810500539

Email: pdkaran@panaceabiotec.com

Web: www.panaceabiotec.com